The FDA’s new support of a single study approach has drawn much discussion, raising questions as to whether conducting just one confirmatory study is a risky position for sponsors to take. In this blog, Andrew Garrett,...
-
ICON reports third quarter 2024 results
ICON plc today reported its financial results for the third quarter ended September 30, 2024
-
ICON survey highlights scale of focus on precision therapies in increasingly complex oncology landscape
ICON plc today announced results from a recent survey of over 100 professionals engaged in oncology drug development to understand the current state of emerging oncology treatment development, including the associated clinical trial dynamics.
-
ICON announces appointment of new Chief Financial Officer (CFO)
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced the appointment of Nigel Clerkin as its new Chief Financial Officer (CFO).
-
ICON reports second quarter 2024 results
ICON plc today reported its financial results for the second quarter ended June 30, 2024.
-
ICON announces results of Annual General Meeting and changes to the Board of Directors
ICON plc announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 23, 2024 were duly passed by shareholders.
-
ICON recognised for leadership position in clinical research industry and as socially responsible employer
At the CRO Leadership Awards 2024, ICON was recognised for its excellence in clinical research in all categories.
-
ICON hosts investor day and updates full year 2024 financial guidance
ICON plc will host its 2024 Investor Day today in New York City.
-
ICON plc to hold Investor Day meeting on May 30, 2024
This press release contains forward-looking statements, including statements about our financial guidance.
-
ICON releases its ICON Cares 2023 Report
This outlines how the company is delivering on its ESG, diversity, inclusion and belonging, and CSR goals, as delivered through its ICON Cares program.
-
ICON announces pricing of USD 2 billion notes
Consisting of $750,000,000 5.809% Senior Secured Notes due 2027, $750,000,000 5.849% Senior Secured Notes due 2029 and $500,000,000 6.000% Senior Secured Notes due 2034 (collectively, the “Notes”).
